HCV

Discussion in 'Gilead Sciences' started by anonymous, Aug 4, 2020 at 5:39 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Just saw a job posting. Is this still a viable position. Seems the market is skrinkijg rapidly.
     

  2. anonymous

    anonymous Guest

    depends on the territory/market it’s in. If there’s a big addiction market, that’s the future. Everyone else has been cured or died
     
  3. anonymous

    anonymous Guest

    Any glimmer of hope that HCV stays relevant? RA isn’t going to get to market, NASH bombed so what will HCV offer??
     
  4. anonymous

    anonymous Guest

    Market shrinking. Some territories have collapsed. You need to sales and market development.
     
  5. anonymous

    anonymous Guest

    Market shrinking. This is sales and mkt development position. Some territory’s have collapsed.
     
  6. anonymous

    anonymous Guest


    Yeah, turning to addiction medicine to fill the void. 3/4 relapse multiple times and don’t give a shit about HCV infection
     
  7. anonymous

    anonymous Guest

    How successful is this division and products? What is the salary range? Any info greatly appreciated.
     
  8. anonymous

    anonymous Guest


    Best days behind it. It’s a cure market with the hardest to get on treatment in the future
     
  9. anonymous

    anonymous Guest

    What is the salary range
     
  10. anonymous

    anonymous Guest

    Cheap
     
  11. anonymous

    anonymous Guest

    Abbvie owns the market. Best consider Abbvie for future growth.
     
  12. anonymous

    anonymous Guest


    Can you validate that?? I left some time ago when the writing was on the wall and the well was drying up. I thought the authorized generics level set the pricing bullshit.
     
  13. anonymous

    anonymous Guest

    That’s false - Abbvie did ok for a couple years by slashing the price, but Gilead is market leader once again. Products don’t compare, price is all Abbvie has - it is a shrinking market as Gilead’s products cured tens of thousands of patients. Growth at Gilead is in HIV treatment, Oncology, and hopefully NASH or Fingo.
     
  14. anonymous

    anonymous Guest


    Gilead is a has been pharma co. Filgo flopped, NASH flopped, Yescarta isn’t living up to the hype and HCV is fading.
     
  15. anonymous

    anonymous Guest

    Anyone having field rides with their manager?
     
  16. anonymous

    anonymous Guest


    Maybe. Not saying anymore
     
  17. anonymous

    anonymous Guest

    KD’s tram is.. same reps every week.
     
  18. anonymous

    anonymous Guest


    Shocking, would have been my first guess. HD must be protecting him as usual
     
  19. anonymous

    anonymous Guest

    At any other company, psycho dude KD would have been escorted out the door. Shameful what he’s been able to get away with.
     
  20. anonymous

    anonymous Guest

    Nope, BV just continues to put in fake ride days for us :rolleyes: he is striving for average as usual!